The Journal of Urology
Volume 183, Issue 1 , Pages 11-12 , January 2010

Are Biomarkers for Bladder Cancer Beneficial?

  • H. Barton Grossman

      Affiliations

    • Financial interest and/or other relationship with Ferring, Photocure, Abbott Molecular, GE Healthcare and Viventia Biotechnologies.

References 

  1. Wu X, Ye Y, Kiemeney LA, et al. Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet. 2009;41:991
  2. Heney NM, Nocks BN, Daly JJ, et al. Ta and T1 bladder cancer: location, recurrence and progression. Br J Urol. 1982;54:152
  3. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466
  4. Glatz K, Willi N, Glatz D, et al. An international telecytologic quiz on urinary cytology reveals educational deficits and absence of a commonly used classification system. Am J Clin Pathol. 2006;126:294
  5. Sarosdy MF, Schellhammer P, Bokinsky G, et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol. 2002;168:1950
  6. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859
  7. Ruggeri EM, Giannarelli D, Bria E, et al. Adjuvant chemotherapy in muscle-invasive bladder carcinoma: a pooled analysis from phase III studies. Cancer. 2006;106:783
  8. Porter MP, Kerrigan MC, Donato BM, et al. Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer. Urol Oncol. 2009;Epub ahead of print

PII: S0022-5347(09)02719-0

doi: 10.1016/j.juro.2009.10.052

The Journal of Urology
Volume 183, Issue 1 , Pages 11-12 , January 2010

Article Tools